Click here to view online. Add this email to your safelist.
Lynparza meets primary endpoint in Phase III trial in BRCA-mutated metastatic breast cancer
17 February 2017
Lynparza provided a statistically-significant improvement in progression-free survival compared to chemotherapy First positive randomised trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
